Livia C M Rodrigues1, Pedro H Gobira2, Antonio Carlos de Oliveira2, Renan Pelição1, Antonio Lucio Teixeira3, Fabricio A Moreira2, Alline Cristina Campos3. 1. 1Department of Physiological Sciences,Health Science Center,Universidade Federal do Espírito Santo,Vitoria,Brazil. 2. 2Department of Pharmacology,Institute of Biological Sciences,Universidade Federal de Minas Gerais,Belo Horizonte,Brazil. 3. 3Group of Neuroimmunology,Laboratory of Immunopharmacology,Institute of Biological Sciences,Universidade Federal de Minas Gerais,Belo Horizonte,Brazil.
Abstract
OBJECTIVE: Substance dependence disorder is a chronically relapsing condition characterised by neurobiological changes leading to loss of control in restricting a substance intake, compulsion and withdrawal syndrome. In the past few years, (endo)cannabinoids have been raised as a possible target in the aetiology of drug addiction. On the other hand, although the exact mechanisms of the genesis of addiction remain poorly understood, it is possible that neuroinflammation might also play a role in the pathophysiology of this condition. Studies demonstrated that (endo)cannabinoids act as immunomodulators by inhibiting cytokines production and microglial cell activation. Thus, in the present review, we explore the possible role of neuroinflammation on the therapeutic effects of cannabinoids on drug addiction. METHODS: We conducted an evidence-based review of the literature in order to assess the role of cannabinoids on the neuroinflammatory hypothesis of addiction (terms: addiction, cannabinoids and inflammation). We searched PubMed and BioMedCentral databases up to April 2014 with no date restrictions. RESULTS: In all, 165 eligible articles were included in the present review. Existing evidence suggests that disruption in cannabinoid signalling during the drug addiction process leads to microglial activation and neuroinflammation. CONCLUSION: The literature showed that inflammation and changes in endocannabinod signalling occur in drug abuse; however, it remains uncertain whether these changes are causally or coincidentally associated with addiction. Additional studies, therefore, are needed to elucidate the contribution of neuroinflammation on the behavioural and neuroprotective effects of cannabinoids on drug addiction.
OBJECTIVE:Substance dependence disorder is a chronically relapsing condition characterised by neurobiological changes leading to loss of control in restricting a substance intake, compulsion and withdrawal syndrome. In the past few years, (endo)cannabinoids have been raised as a possible target in the aetiology of drug addiction. On the other hand, although the exact mechanisms of the genesis of addiction remain poorly understood, it is possible that neuroinflammation might also play a role in the pathophysiology of this condition. Studies demonstrated that (endo)cannabinoids act as immunomodulators by inhibiting cytokines production and microglial cell activation. Thus, in the present review, we explore the possible role of neuroinflammation on the therapeutic effects of cannabinoids on drug addiction. METHODS: We conducted an evidence-based review of the literature in order to assess the role of cannabinoids on the neuroinflammatory hypothesis of addiction (terms: addiction, cannabinoids and inflammation). We searched PubMed and BioMedCentral databases up to April 2014 with no date restrictions. RESULTS: In all, 165 eligible articles were included in the present review. Existing evidence suggests that disruption in cannabinoid signalling during the drug addiction process leads to microglial activation and neuroinflammation. CONCLUSION: The literature showed that inflammation and changes in endocannabinod signalling occur in drug abuse; however, it remains uncertain whether these changes are causally or coincidentally associated with addiction. Additional studies, therefore, are needed to elucidate the contribution of neuroinflammation on the behavioural and neuroprotective effects of cannabinoids on drug addiction.
Authors: David De Sa Nogueira; Romain Bourdy; Rafael Alcala-Vida; Dominique Filliol; Virginie Andry; Yannick Goumon; Jean Zwiller; Pascal Romieu; Karine Merienne; Mary C Olmstead; Katia Befort Journal: Mol Neurobiol Date: 2022-01-15 Impact factor: 5.590
Authors: Valéria de Almeida; Gabriela Seabra; Guilherme Reis-de-Oliveira; Giuliana S Zuccoli; Priscila Rumin; Mariana Fioramonte; Bradley J Smith; Antonio W Zuardi; Jaime E C Hallak; Alline C Campos; José A Crippa; Daniel Martins-de-Souza Journal: Eur Arch Psychiatry Clin Neurosci Date: 2022-05-27 Impact factor: 5.760
Authors: Carmen Ferrer-Pérez; Tamara Escrivá Martinez; Sandra Montagud-Romero; Raúl Ballestín; Marina D Reguilón; José Miñarro; Marta Rodríguez-Arias Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240